Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab versus pertuzumab + trastuzumab for residual HER2-positive breast cancer after neoadjuvant therapy
ChiCTR2000040866Phase 4Recruiting
- Sponsor
- Suining Central Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer comparing Pyrotinib + trastuzumab with Pertuzumab + trastuzumab (2 arms). Primary endpoint: Invasive disease-free survival. Started Jan 2021; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000040866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040866.